Kidney Cancer

Drug duos that hit kidney cancer with immunotherapy and targeted treatment offer a better alternative to single agents.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

The tumors of patients with non-small cell lung and renal cell cancer shrunk following treatment with pegilodecakin plus immunotherapy.

From a Hallmark Channel actor revealing a kidney cancer diagnosis to a donor match first-time meeting 20 years later, here’s what is making headlines in the cancer space this week.

Patients with renal cell carcinoma who were treated with a targeted therapy lived three months longer than people who received older treatments.

One expert discusses the “extremely interesting and extremely dynamic” field of renal cell carcinoma, and how recent research and FDA actions could offer hope for patients and their doctors.

In assessing the quality of family cancer history entered into electronic health records, researchers found that such reporting was suboptimal – highlighting the need to optimize online collection with a provider-free approach.

Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

An international study of nearly 2,000 patients with renal cell carcinoma exposed many unmet needs across all stages of disease.

Patients with advanced renal cell carcinoma have new first-line therapy options.

The Food and Drug Administration approved the combination use of Bavencio plus Inlyta for the first-line treatment of patients with advanced renal cell carcinoma.

With the growing price of cancer treatment, researchers evaluated the cost-effectiveness of the new standard-of-care in frontline metastatic renal cell carcinoma.

Kidney cancer survivors who follow recommendations for physical activity experience improved quality of life, but few individuals adhere to the guidelines, according to recent findings.

With patient resistance to single-agent immunotherapies in the treatment of advanced renal cell carcinoma, new combination therapies are needed in the frontline setting.

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.

The Food and Drug Administration approved Keytruda in combination with Inlyta for the frontline treatment of patients with advanced renal cell carcinoma.

The combination use of Keytruda plus Inlyta significantly improved survival outcomes among patients with previously untreated advanced renal cell carcinoma – the most common type of kidney cancer.